- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01502579
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
August 27, 2013 updated by: Wei Shi, Guangdong Provincial People's Hospital
An Observational Study of the Relationship Between Pathological Variants and Clinical Data at Presentation and Follow-up in IgA Nephropathy
The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function.
This study is aimed to identify the potential relationship between pathological variants and clinical data in IgA nephropathy.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
603
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Guangdong General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The population from which the cohort will be selected is these who have received renal biopsy in Guangdong General Hospital
Description
Inclusion Criteria:
- biopsy-proven IgA nephropathy;
Exclusion Criteria:
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
glomerular filtration rate decline or end-stage renal disease or doubling of serum creatinine
Time Frame: after the biopsy
|
after the biopsy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
August 1, 2013
Study Registration Dates
First Submitted
December 29, 2011
First Submitted That Met QC Criteria
December 29, 2011
First Posted (Estimate)
December 30, 2011
Study Record Updates
Last Update Posted (Estimate)
August 28, 2013
Last Update Submitted That Met QC Criteria
August 27, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GGH201106
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IgA Nephropathy
-
Josep M CruzadoWyeth is now a wholly owned subsidiary of PfizerCompletedGlomerulonephritis, IGA | IGA Nephropathy | Nephropathy, IGASpain
-
Visterra, Inc.CompletedImmunoglobulin A Nephropathy | IgA Nephropathy | IgAN - IgA NephropathyUnited States
-
Rigel PharmaceuticalsCompletedIGA NephropathyUnited States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
-
Uppsala University HospitalHaukeland University Hospital; University Hospital, Linkoeping; Smerud Medical...UnknownIGA NephropathyNorway, Sweden
-
Calliditas Therapeutics ABArchimedes Development LtdCompletedIGA NephropathySweden
-
Sun Yat-sen UniversityUnknownIGA NephropathyChina
-
Guangdong Provincial People's HospitalCompletedGlomerulonephritis | IGA NephropathyChina
-
Nanjing University School of MedicineCompleted
-
Rigel PharmaceuticalsWithdrawn
-
Zhi-Hong Liu, M.D.Completed